| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results |
| 19 Oct 2026 | SCHEDULE 13G |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology |
| 29 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel |
| 09 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collate... |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 60,530,293 shares of the Company’s common stock outstanding as of March 30, 2026, the record date for... |
| 29 May 2026 |
Form 4: Clark Ian T, Director
Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy) |
| 29 May 2026 |
Form 4: Cohen Fred E, Director
Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy) |
| 29 May 2026 |
Form 4: Seidenberg Beth C, Director
Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy) |
| 29 May 2026 |
Form 4: Shaw Christi, Director
Gave up 4,194 shares to cover exercise price or tax ($36K) |
| 29 May 2026 |
Form 4: Aktar Mert, Director
Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy) |
| 20 May 2026 |
Form 4: Martini Gregory S., Chief Financial Officer
Granted 325,000 Stock Option (right to buy) |
| 20 May 2026 |
Form 3: Martini Gregory S., Chief Financial Officer
No securities owned |
| 18 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on May 18, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and... |
Loading...